PET and PET/CT imaging of skeletal metastases

Cancer Imaging

Volumn 10, Issue 1, 2010, Pages 153-160

  Cook, Gary J R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Positron emission tomography; Skeletal metastases

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORIDE RA 223; CHOLINE F 18; DOTATOC GA 68; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; IODINE 131; MEDRONATE TECHNETIUM TC 99M; TRACER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; ESOPHAGUS CARCINOMA; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; NASOPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; THYROID CANCER;

EID: 77958563976     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.0022     Document Type: Review

References (53)

1. Galasko CSB. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert AH, editors. Bone metastases. Boston: MK Hall; 1981, p. 49-63.
2. Rubens RD. Bone metastases - incidence and complications. In: Rubens RD, Mundy GR, editors. Cancer and the skeleton. London: Martin Dunitz; 2000, p. 33-42.
3. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3: 332-4.
4. 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31: 28-49. doi:10.1053/snuc.2001.18742. PMid:11200203.
5. 18F in rabbit bone. Clin Phys Physiol Measurement 1986; 7: 333-43. doi:10.1088/0143- 0815/7/4/003. PMid:3791879.
6. Bang S, Baud CA. Topographical distribution of fluoride in iliac bone of a fluoride-treated osteoporotic patient. J Bone Mineral Res 1990; 5(Suppl 1), S87-9. doi:10.1002/jbmr.5650051313. PMid:2339642.
7. Narita N, Kato K, Nakagaki H, et al. Distribution of fluoride concentration in the rat's bone. Calcified Tissue Int 1990; 46: 200-4. doi:10.1007/BF02555045. PMid:2106380.
8. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49: 68-78. doi:10.2967/jnumed.106.037200. PMid:18077529.
9. 18F-fluoride measured with PET in correlation with CT. Skeletal Radiol 1998; 27: 72-76. doi:10.1007/s002560050340.
10. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Chilton, Didcot: Health Protection Agency; 2006.
11. 18F PET. J Nucl Med 1999; 40: 1623-9.
12. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and PET. J Clin Oncol 1999; 17: 2381-9.
13. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42: 1800-4.
14. Hetzel M, Arslandemir C, Konig HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness and impact on patient management. J Bone Miner Res 2003; 18: 2206-14. doi:10.1359/jbmr.2003. 18.12.2206. PMid:14672356.
15. 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging 2009; 36: 1807-12. doi:10.1007/s00259-009-1181-2.
16. 18F-fluoride PET/CT. J Nucl Med 2004; 45: 272-8.
17. 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-97.
18. Hoegerle S, Juengling F, Otte A, et al. Combined FDG and F-18 fluoride whole body PET: a feasible two in one approach to cancer imaging. Radiology 1998; 209: 253-8.
19. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot phase study. J Nucl Med 2009; 50: 501-5. doi:10.2967/jnumed.108.058339. PMid:19289439.
20. 18F fluoride PET/CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35: 1766-74. doi:10.1007/s00259-008-0788-z. PMid:18465129.
21. Beneshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2010; 12: 98-107. doi:10.1007/s11307-009-0239-7. PMid:19588206.
22. http://www.ami-imaging.org/index.php?option=com-content@task=view@id= 173&Itemid=119.
23. 18F-fluoride PET to monitor response in skeletal metastases from prostate cancer treated with Alpharadin (223-Ra-chloride). Nucl Med Commun 2009; 30: 374.
24. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-7. doi:10.1007/s002590050291.
25. Chung JK, Kim YK, Yoon JK, et al. Diagnostic usefulness of F-18 FDG whole body PET in detection of bony metastases compared to Tc-99m MDP bone scan. J Nucl Med 1999; 40: 96P.
26. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40: 1407-13.
27. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-46. (Pubitemid 28193885)
28. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16: 603-9.
29. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine- mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1998; 23: 93-8. doi:10.1097/00003072- 199802000-00007. PMid: 9481497.
30. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer; comparison with 99mTc-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-9. doi:10.1097/00006231-200108000- 00005. PMid:11473206.
31. Yang SN, Liang JA, Lin FJ, Kao CH, Liu CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose PET and Tc-99m MDP bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128: 325-8.
32. 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19: 573-9. doi:10.1007/ BF02985050. PMid:16363622.
33. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9.
34. Hugye V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009; 34: 417-20. doi:10.1097/RLU.0b013e3181a7d03c. PMid:19542943.
35. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Accuracy of FDG PET for diagnosis of single bone metastasis: comparison with bone scintigraphy. J Comput Assist Tomogr 2007; 31: 812-9. doi:10.1097/rct.0b013e318031cc4d. PMid:17895798.
36. Israel O, Goldberg A, Nachtigal A, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging 2006; 33: 1280-4. doi:10.1007/s00259-006- 0141-3. PMid: 16791597.
37. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1253-8. doi:10.1007/s00259-005-1842-8. PMid:16133397.
38. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 FDG PET in the diagnosis of tumor recurrence and metastases in the follow up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38: 250-6. doi:10.1097/00004424-200305000-00002. PMid:12750613.
39. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005; 184: 1266-73.
40. 18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25: 3440-7. doi:10.1200/JCO.2007.11.2854. PMid:17592153.
41. 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007; 48: 889-95. doi:10.2967/jnumed.106.039479. PMid:17504877.
42. 18F]FDG PET is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006; 24: 599-604. doi:10.1200/JCO.2005.03.8760. PMid:16446332.
43. Kato H, Miyazaki T, Nakajima M, et al. Comparison between whole body PET and bone scintigraphy in evaluating bony metastases of esophageal carcinoma. Anticancer Res 2005; 25: 4439-44.
44. Fujimoto R, Higashi T, Nakamoto Y, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006; 20: 399-408. doi:10.1007/BF03027375. PMid:16922468.
45. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro- D-glucose. Radiology 1996; 199: 751-6.
46. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23: 693-7. doi:10.1016/0969-8051(96)00044-3.
47. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer detection of bone metastases in breast cancer by 18 FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625-32.
48. Taira AV, Herfkens RJ, Gambhir SS, Quon A. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology 2007; 243: 204-11. doi:10.1148/radiol.2431052104. PMid:17392254.
49. 18FFDG PET/CT. J Nucl Med 2004; 45: 279-84.
50. Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9: 913-21. doi:10.1016/S1076-6332(03)80461-0.
51. 18F] fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007; 105: 87-94. doi:10.1007/s10549-006-9435-1. PMid:17268819.
52. Schmid HP, Gregorin J, Altwein JE. Growth hormone inhibitors in prostate cancer: a systematic analysis. Urol Int 2008; 81: 17-22. doi:10.1159/000137635. PMid:18645266.
53. Luboldt W, Zophel K, Wunderlich G, et al. Visualisation of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. Mol Imaging Biol 2010; 12: 78-84. doi:10.1007/s11307-009-0230-3. PMid:19421819.